MiR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases

Asian Journal of Andrology

Volumn 15, Issue 2, 2013, Pages 226-230

  Amankwah, Ernest K ^a   Anegbe, Evelyn ^a   Park, Hyun ^a   Pow Sang, Julio ^a   Hakam, Ardeshir ^a   Park, Jong Y ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

miR 21; miR 221; miR 222; miRNA; obesity; prostate carcinoma; recurrence

Indexed keywords

MICRORNA 21; MICRORNA 221; MICRORNA 222;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; GENE EXPRESSION; GLEASON SCORE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBESITY; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION;

AGED; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OBESITY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RNA, NEOPLASM; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84874613115     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2012.160     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Cancer facts and figures. Atlanta, GA: American Cancer Society, 2010.
3. Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ et al. Obesity and survival after radical prostatectomy: a 10-year prospective cohort study. Cancer 2006; 107: 521-9.
4. Amankwah EK, Park JY. miRNA and human prostate cancer. In: Sahu SC (ed). Toxicology and Epigenetics. 1st edn. Hoboken: Wiley, John and Sons, Incorporated, 2012.
5. Fendler A, Jung M, Stephan C, Honey RJ, Stewart RJ et al. miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. Int J Oncol 2011; 39: 1183-92.
6. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A et al. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol 2011; 185: 1118-22.
7. Long Q, Johnson BA, Osunkoya AO, Lai YH, Zhou W et al. Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy. Am J Pathol 2011; 179: 46-54.
8. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010; 126: 1166-76.
9. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010; 127: 394-403.
10. Tong AW, Fulgham P, Jay C, Chen P, Khalil I et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009; 16: 206-16.
11. Alexander R, Lodish H, Sun L. MicroRNAs in adipogenesis and as therapeutic targets for obesity. Expert Opin Ther Targets 2011; 15: 623-36.
12. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2011; 4: 486-501.
13. Hudson RS, Yi M, Esposito D, Glynn SA, Starks AM et al. MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene e-pub ahead of print 17 September 2012.
14. Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res 2012; 40: 3689-703.
15. Zhou X, Marian C, Makambi KH, Kosti O, Kallakury BV et al. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PLoS One 2012; 7: e39011.
16. Li T, Li RS, Li YH, Zhong S, Chen YY et al. miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol 2012; 187: 1466-72.
17. Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B et al. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene 2012; 31: 4460-71.
18. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011; 71: 326-31.
19. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 2012; 72: 1469-77.
20. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011; 71: 326-31.
21. Ribas J, Ni X, Haffner M, Wentzel EA, SalmasiAHet al. miR-21: an androgen receptorregulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009; 69: 7165-9.
22. Ribas J, Lupold SE. The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle 2010; 9: 923-9.
23. Esau C, Davis S, Murray SF, Yu XX, Pandey SK et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87-98.
24. Lin Q, Gao Z, Alarcon RM, Ye J, Yun Z. A role of miR-27 in the regulation of adipogenesis. FEBS J 2009; 276: 2348-58.
25. Xie H, Lim B, Lodish HF. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 2009; 58: 1050-7.
26. Xie H, Sun L, Lodish HF. Targeting microRNAs in obesity. Expert Opin Ther Targets 2009; 13: 1227-38.
27. Hulsmans M, de Keyzer D, Holvoet P. MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis.FASEB J 2011; 25: 2515-27.
28. Parra P, Serra F, Palou A. Expression of adipose microRNAs is sensitive to dietary conjugated linoleic acid treatment in mice. PLoS One 2010; 5: e13005.
29. Lee EK, Lee MJ, Abdelmohsen K, Kim W, Kim MM et al. miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol 2011; 31: 626-38.
30. Keller P, Gburcik V, Petrovic N, Gallagher IJ, Nedergaard J et al. Gene-chip studies of adipogenesis-regulated microRNAs in mouse primary adipocytes and human obesity. BMC Endocr Disord 2011; 11: 7.
31. Kim YJ, Hwang SH, Cho HH, Shin KK, Bae YC. MicroRNA 21 regulates the proliferation of human adipose tissue-derived mesenchymal stem cells and high-fat diet-induced obesity alters microRNA 21 expression in white adipose tissues. J Cell Physiol 2012; 227: 183-93.
32. Chartoumpekis DV, Zaravinos A, Ziros PG, Iskrenova RP, Psyrogiannis AI et al. Differential expression of microRNAs in adipose tissue after long-term high-fat dietinduced obesity in mice. PLoS One 2012; 7: e34872.
33. Terao M, Fratelli M, Kurosaki M, Zanetti A, Guarnaccia V et al. Induction of miR-21 by retinoic acid in estrogen receptor-positive breast carcinoma cells: biological correlates and molecular targets. J Biol Chem 2011; 286: 4027-42.
34. Durai R, Davies M, Yang W, Yang SY, Seifalian A et al. Biology of insulin-like growth factor binding protein-4 and its role in cancer (review). Int J Oncol 2006; 28: 1317-25.
35. Massoner P, Ladurner Rennau M, Heidegger I, Kloss-Brandstä tter A, Summerer M et al. Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-beta treatment. Am J Pathol 2011; 179: 2905-19.
36. Ribarska T, Bastian KM, Koch A, Schulz WA. Specific changes in the expression of imprinted genes in prostate cancer-implications for cancer progression and epigenetic regulation. Asian J Androl 2012; 14: 436-50.
37. Liu LZ, Li C, Chen Q, Jing Y, Carpenter R et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One 2011; 6: e19139.